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Mechanism of generation of bone disease in multiple myeloma and its treatment
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SUMMARY
Multiple myeloma (MM) is characterized by accumulation of monoclonal plasma cells in
the bone marrow and formation of devastating lytic bone lesions. In these lesions MM cells
reside in the proximity of stromal cells and osteoclasts (OCs). We have found that C-C
chemokines, macrophage inflammatory protein (MIP)-1α and MIP-1β, secreted from most of
MM cells potently enhance OC formation and activation. These effects are mostly abro-
gated by neutralizing antibodies against MIP-1α and MIP-1β in combination, suggesting
critical roles for these chemokines in the development of lytic bone lesions. These
chemokines induce expression of RANK ligand, a key molecule of osteoclastogenesis, by
marrow stromal cells. Furthermore, OC formation and activation induced by MM cells as
well as MIP-1α and MIP-1β are almost completely blocked by a surplus of osteoprotegerin, a
soluble inhibitor for RANK ligand. These results demonstrate that the osteoytic effects of
MM cells are mediated by MIP-1 in a RANK ligand-dependent manner. Interestingly, OCs
generated from peripheral blood mononuclear cells enhance survival and growth of MM
cells in vitro . The OC effects are only partially inhibited by anti-IL-6 but strongly by contact
inhibition between MM cells and OCs, suggesting involvement of IL-6-independent
contact-mediated mechanism(s). Taken together, a cellular interplay between MM cells
and OCs stimulates their growth and activity, thereby forming a vicious cycle that leads to
extensive bone destruction and MM expansion. Bisphosphonates are a potent anti-bone
resorptive agent and show effective palliation of bone pain and improvement of quality of life
in patients with an advanced disease. Clinical trials with newly developed anti-resorptive
agents are ongoing. However, their role in prophylaxis, long-term efficacy and optimal
therapeutic schedules remain to be established from well-designed clinical trials.
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